throbber
Page 1
`
` S. Narasimha Murthy, Ph.D.
` UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
` CASE NO. IPR2018-00168
` U.S. PATENT NO. 9,549,938
`
`FLATWING PHARMACEUTICALS, LLC, PETITIONER
`
`VERSUS
`
`ANACOR PHARMACEUTICALS, INC., PATENT OWNER
`**************************************************
` DEPOSITION OF
` S. NARASIMHA MURTHY, PH.D.
`**************************************************
` APPEARANCES NOTED HEREIN
`
` DATE: AUGUST 20, 2018
` PLACE: MAYO MALLETTE PLLC
` 2094 OLD TAYLOR ROAD
` OXFORD, MISSISSIPPI
` TIME: 9:08 A.M.
`
`REPORTED BY: TODD J. DAVIS
` BCR, CSR #1406, RPR
`JOB NUMBER: 146558
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`
`3
`
`4 5
`
`6
`
`7 8
`
`9
`10
`11
`12
`13
`14
`
`15
`
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`Page 1
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 2
`
` S. Narasimha Murthy, Ph.D.
`APPEARANCES:
`
` PHILIP SEGREST, JR., ESQ.
` Husch Blackwell
` 120 South Riverside Plaza
` Chicago, Illinois 60606
` COUNSEL FOR PETITIONER
`
` AARON MAURER, ESQ.
` ANTHONY SHEH, ESQ.
` Williams & Connolly
` 725 Twelfth Street, NW
` Washington, DC 20005
` COUNSEL FOR PATENT OWNER
`
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`
`3 4
`
`5
`
`6
`
`7 8 9
`
`10
`
`11
`
`12
`
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`Page 2
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 3
`
` S. Narasimha Murthy, Ph.D.
` INDEX
`Style and Appearances ..................... 1
`Index ..................................... 3
`Examination by Mr. Maurer ................. 4
`Certificate of Court Reporter ............. 102
`Certificate of Deponent ................... 103
`
`EXHIBITS:
`Exhibit 1005-A Declaration of Dr. Murthy... 5
`Exhibit 1005-B Declaration of Dr. Murthy... 5
`Exhibit 1005-C Declaration of Dr. Murthy... 5
`Exhibit 1001-C U.S. Patent................. 7
`Exhibit 2008 Journal.................... 79
`Exhibit 2007 Drug Delivery.............. 63
`Exhibit 2009 Article.................... 69
`Exhibit 2004 Article.................... 36
`Exhibit 2002 Transcript................. 13
`Exhibit 2003 Transcript................. 13
`Exhibit 2005 Research Paper............. 47
`Exhibit 2006 Article.................... 49
`Exhibit 1001-A U.S. Patent................. 6
`Exhibit 1001-B U.S. Patent................. 7
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`
`8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`Page 3
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 4
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` S. NARASIMHA MURTHY, PH.D.,
`having been first duly sworn, was examined and
`testified under oath as follows:
`EXAMINATION BY MR. MAURER:
` Q. Okay. Good morning.
` A. Good morning.
` Q. Can you please state your name and
`address?
` A. My name is S. Narasimha Murthy. My
`address is 501 Bowie Drive, Oxford, Mississippi
`38655.
` Q. And you're appearing here today as an
`expert witness on behalf of Flatwing
`Pharmaceuticals; is that correct?
` A. That's correct.
` Q. And you have submitted as an expert four
`declarations and four separate IPRs on Flatwing's
`behalf, correct?
` A. Correct.
` Q. And do you understand that the
`deposition that is being taken here today is a
`combined deposition for each of those four
`proceedings?
` A. Correct. I understand.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 4
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 5
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` Q. Okay. I have handed you or put in front
`of you some papers that have been premarked.
`These are the four declarations that you submitted
`in each of those four IPRs --
` MR. MAURER: And, Philip, you have these
` as well.
` (Exhibit 1005-A marked for
` identification.)
` (Exhibit 1005-B marked for
` identification.)
` (Exhibit 1005-C marked for
` identification.)
`BY MR. MAURER:
` Q. And the four patents that are at issue.
`Let me explain that because they have been
`previously marked all with the same -- with
`overlapping numbers, we have taken the liberty of
`assigning them differentiators here.
` So if you look in front of you, you
`will see that your declaration in the
`IPR2018-00168, which is about the 938 patent, is
`marked Exhibit 1005.
` A. Okay. Yeah.
` Q. Okay. The -- your declaration in IPR
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 5
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 6
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`169, which is about the 289 patent, we've marked
`as Exhibit 1005-A.
` A. Uh-huh (affirmative response).
` Q. We marked your declaration in the 0170
`IPR against the 290 patent as Exhibit 1005-B. And
`we've marked your final declaration in IPR 0171,
`which is against the 823 patent, as Exhibit
`1005-C.
` Do you see that?
` A. Yes.
` Q. All right. You've got all those there
`in front of you; and if you ever need to refer to
`them during the course of the day, that's fine.
`You're free to do so.
` A. Yeah.
` Q. Likewise, the patents were marked with
`overlapping numbers in these four different
`proceedings, so we have given them different
`identifiers.
` A. Uh-huh (affirmative response).
` Q. And I placed those in front of you.
` A. Okay.
` (Exhibit 1001-A marked for
` identification.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 6
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 7
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` (Exhibit 1001-B marked for
` identification.)
` (Exhibit 1001-C marked for
` identification.)
`BY MR. MAURER:
` Q. The 938 patent is Exhibit 1001.
` A. Uh-huh (affirmative response).
` Q. And the 289 patent is Exhibit 1001-A.
`The 290 patent is Exhibit 1001-B, and the 823 is
`1001-C.
` A. Okay.
` Q. And if, again, you need to refer to
`those at any point today, you should feel free to
`do so.
` Are you aware that there have
`been --
` MR. SEGREST: Before we get into the
` questioning, I actually thought we were going
` to do appearances on the record, so --
` MR. MAURER: I was going to do that,
` too.
` MR. SEGREST: But that's fine.
` We did have an objection to the notice
` only to the extent that it exceeds the scope
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 7
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 8
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` of cross-examination permitted, and only
` to -- except to note that the parties have
` agreed to allow the use of previous
` depositions in the cases IPR2015-1776, -1780,
` and -1785. But Petitioner notes that the
` parties agreed to allow the use of that
` previous deposition testimony to the extent
` it's relevant on the issues, including
` background of the witness and prior art
` references that are common to those
` proceedings and this one.
` We reserve the right to object to
` testimony that may have been taken in that
` proceeding. It's not relevant to this one.
` It's relating only to the patent in that
` proceeding.
` Petitioner also reserves the right to --
` additionally, Petitioner reserves the right
` to object in this deposition to any
` particular questions, regardless of whether
` similar objections were or could have been
` interposed in that previous deposition.
` MR. MAURER: Anything else?
` MR. SEGREST: No.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 8
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 9
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` MR. MAURER: Did you want us to put our
` appearances on the record, sir?
` COURT REPORTER: No. I've got them all
` right here.
` MR. MAURER: Okay.
`BY MR. MAURER:
` Q. Are you aware that other IPRs have been
`filed regarding the patents that are marked as
`Exhibit 1001 and A through C by Mylan?
` A. By whom?
` Q. Mylan Pharmaceutical?
` A. No. I'm not aware of it.
` Q. So you've never had any communications
`with representatives of Mylan or counsel for
`Mylan?
` A. No.
` Q. Okay. Let's look, if we could, at --
`and it doesn't really matter which of the
`declarations because they are substantial --
`there's substantial overlap.
` But let's look at, why don't we
`say, 1005, the declaration for the 938 patent.
` A. Okay.
` Q. And I'm going to ask you to turn to
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 9
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 10
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`paragraph 10.
` A. Uh-huh (affirmative response).
` Q. On -- paragraph 10 on Page 3.
` A. Paragraph 10. Sorry.
` Q. It's paragraph 10, not Page 10. Sorry.
` Are you with me?
` A. Uh-huh (affirmative response).
` Q. Because this deposition is being
`recorded stenographically, if you are giving a --
`I'm going to ask you to give a verbal answer, and
`if you're answering affirmative to say "yes"
`instead of uh-huh --
` A. Okay.
` Q. -- or in the negative, "no" instead of
`uh-uh because otherwise it's not clear on the
`transcript. Okay?
` A. Sure.
` Q. Thank you. And in paragraph 10, there's
`a list of materials considered by you in forming
`your opinions; is that right?
` A. Uh-huh (affirmative response). Right.
` Q. Is that yes?
` A. Yes.
` Q. And for the materials -- strike that
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 10
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 11
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`question.
` Did you review any other materials
`in preparing your opinions with respect to these
`patents?
` A. No.
` Q. And if we turn to the last page of
`Exhibit 1005, is that your signature there?
` A. Right.
` Q. And did you read your declarations
`carefully before signing them?
` A. Yes, I did.
` Q. And that's true for all of the
`declarations?
` A. True for all of them.
` Q. And did you see anything that you wanted
`to change in any of your declarations?
` MR. SEGREST: Object to the form.
` A. Well, there are a couple of places where
`we have cited the wrong page number.
`BY MR. SEGREST:
` Q. Okay.
` A. That's the only thing that we -- that I
`noticed.
` Q. Okay.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 11
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 12
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. Otherwise, it's okay.
` Q. Other than the citation errors, those
`page numbers, it's fine?
` A. Yeah.
` Q. If we -- in your report, Exhibit 1005,
`turn to paragraph 23. You have a statement in
`there about the earliest priority date.
` Do you see that?
` A. That's right.
` Q. And is it your understanding that the
`earliest claimed priority date for the 938 patent
`is February 16th, 2005?
` A. That's correct.
` Q. And it's the same priority date for each
`of these patents at issue --
` A. Right.
` Q. -- here, correct?
` A. Correct.
` Q. And that's your understanding as to
`that?
` A. That's right.
` Q. And if I say "priority date" today, you
`will understand that I'm talking about this date,
`correct?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 12
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 13
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. That's right.
` Q. Now, you've testified as an expert
`previously on patents that are related to the ones
`at issue in these IPRs, correct?
` A. Correct.
` Q. And you did that on behalf of the
`Coalition for Affordable Drugs?
` A. Correct.
` Q. In that case you provided declarations
`and deposition testimony. Yes?
` A. Correct.
` MR. MAURER: Let's get Exhibit 2002.
` And 2003. It should be marked already.
` (Exhibit 2002 marked for
` identification.)
` (Exhibit 2003 marked for
` identification.)
`BY MR. MAURER:
` Q. I'm going to mark as Exhibit 2002 a copy
`of the transcript of the proceedings in May of
`2016 that you gave in connection with your work
`for the Coalition for Affordable Drugs.
` A. Okay.
` Q. Do you recall giving that as -- that
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 13
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 14
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`deposition in May --
` MR. SEGREST: Objection under Rule 106.
` I think there's an errata sheet for this, as
` well.
` MR. MAURER: Okay. I'm not sure if we
` have that or not, but we will take note of
` that.
`BY MR. SEGREST:
` Q. So the -- do you recall giving that
`deposition in 2016?
` A. Right.
` Q. And did you review that transcript after
`you gave the deposition?
` A. Yeah, I did.
` Q. And did you find any errors?
` A. There were some errors, and that was
`brought up with the counsel. That was told to the
`counsel.
` Q. And you submitted, then, an errata sheet
`to correct the errors; is that right?
` A. Yeah.
` Q. When did you most recently review this
`transcript, Exhibit 2002?
` MR. SEGREST: Object to form.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 14
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 15
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. It was about a week ago. I just went
`over -- not really review line by line, but I just
`went over the major things.
`BY MR. MAURER:
` Q. And did you see anything when you
`reviewed it that you wanted to correct?
` A. No.
` Q. I'm going to hand you what's been marked
`as Exhibit 2003. This is a transcript of a
`deposition that you gave in those prior IPRs in
`September of 2016.
` Do you see that?
` A. Correct. Yes.
` Q. Did you testify truthfully during that
`deposition?
` A. Yes.
` MR. SEGREST: Objection under 106 again.
` There is an errata sheet that's on file in
` the previous IPR.
`BY MR. MAURER:
` Q. And you reviewed this transcript after
`you testified; is that correct?
` A. After my deposition, you mean?
` Q. Yes.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 15
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 16
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. No.
` Q. You never, to your --
` A. I never reviewed this after.
` Q. Do you remember filling out an errata
`sheet with respect to this deposition?
` A. Yes.
` Q. And how did you come to complete the
`errata sheet if you didn't review the transcript?
` A. No. I reviewed the transcript.
` Q. Okay.
` A. I told you I reviewed the transcript.
`And I told them there were some errors. But I
`didn't review my declaration, and this is a
`declaration, isn't it?
` Q. No, sir. It should be the transcript.
` A. This is transcript again? Okay.
` Q. Yes. You see that's the transcript from
`the deposition that you gave in September of 2016
`in connection with your work for the Coalition for
`Affordable Drugs?
` A. What is this, then?
` Q. You gave two depositions in that case.
` A. Right. Okay.
` Q. Do you agree?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 16
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 17
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. Yeah. Sure. Sure.
` Q. This is the second one.
` A. Okay. This is the second one. Okay.
` Q. And after you gave that deposition, did
`you review this transcript?
` A. Yeah. I think I did.
` Q. And if you found any errors, did you
`correct them on the errata sheet?
` A. Don't recall.
` Q. When did you most recently review that
`transcript?
` A. Again, same time. A week or ten days
`ago.
` Q. Did you see anything in your review that
`you needed to correct?
` A. I didn't look so closely. I just -- you
`know, it was a high leveled reading. I didn't see
`any -- any mistakes.
` Q. Okay. I'm going to hand you what's
`previously been marked in this -- these
`proceedings as Exhibit 1006. It's a copy of your
`CV.
` Is this a copy of your current
`curriculum vitae?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 17
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 18
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` MR. SEGREST: Object to the form.
` A. This is my curriculum vitae. That's
`correct.
`BY MR. MAURER:
` Q. When was that last updated?
` A. Well, this is a very old version. This
`is the version that I gave to the counsel quite
`some time ago. I did not update. I mean, I have
`the updated version, but I did not provide them
`that.
` Q. So since Exhibit 1006 has been provided
`in this case, you've updated your CV; is that
`correct?
` A. I have not given them the updated
`version.
` Q. Right. But you have yourself --
` A. I have the updated version.
` Q. And in the -- what is the approximate
`date of Exhibit 1006?
` A. Contrical -- it should be somewhere in
`2016.
` Q. Did you provide an updated curriculum
`vitae to the counsel for Flatwing Pharmaceutical?
` A. No, I did not.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 18
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 19
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` Q. Is this the same -- Exhibit 1006, is
`this the same curriculum vitae that was submitted
`by -- in connection with the Coalition for
`Affordable Drugs papers?
` A. I think so, yeah.
` Q. How would you describe the focus of your
`research?
` MR. SEGREST: Object to the form.
` A. My research is mainly focused on the
`development of topical products for delivery of
`drugs into skin, into nail. Another research
`areas I work on includes intranasal delivery of
`drugs. Mainly -- mainly in the topical products.
`BY MR. MAURER:
` Q. Do you consider yourself an expert in
`the area of development of topical products for
`the delivery of drugs?
` A. That's correct.
` MR. SEGREST: Object to the form.
`BY MR. MAURER:
` Q. Are you familiar with the term the
`"transungual" drug delivery?
` A. Right. I am.
` Q. What does that mean?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 19
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 20
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. It's delivery of drugs into and across
`the nail plate.
` Q. Are you an -- do you consider yourself
`an expert in transungual drug delivery?
` MR. SEGREST: Object to form.
` A. Yes, I am.
`BY MR. MAURER:
` Q. Okay. Have you ever been involved in
`the development of a drug that has made it onto
`the market?
` MR. SEGREST: Object to form.
` A. No.
`BY MR. MAURER:
` Q. You're not a chemist; is that correct?
` A. I am not a chemist.
` Q. No degrees in chemistry?
` A. I have taken quite a few courses in
`chemistry during my [indecipherable] but I do not
`have a degree in chemistry.
` Q. And your work in connection with the
`Coalition for Affordable Drug IPRs provided your
`first exposure to boron chemistry, correct?
` MR. SEGREST: Object to form.
` A. I didn't get the word. What do you mean
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 20
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 21
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`by "boron chemistry"?
`BY MR. MAURER:
` Q. Chemistry involving compounds that have
`boron as a component -- pharmaceutical compounds
`that have boron as a component.
` A. Well, boron compounds are like quite a
`few we use in the pharmaceutical product
`development. But the chemistry part was not
`really -- no. I did not have much exposure to the
`chemistry -- boron chemistry before, yeah.
` Q. You're not a clinician, correct?
` A. I'm not a clinician.
` Q. Which means you've never treated anyone
`with onychomycosis, right?
` A. No.
` Q. What is onychomycosis?
` A. Onychomycosis is fungal infection of the
`nails.
` Q. I want to clarify. I asked you that
`you've never treated anyone with onychomycosis,
`right? And you said no.
` A. No.
` Q. By that, you mean you had not?
` A. I did not treat.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 21
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 22
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` Q. Have you ever consulted on a particular
`treatment for a patient suffering from
`onychomycosis?
` MR. SEGREST: Object to form.
` A. No.
`BY MR. MAURER:
` Q. Are you a mycologist?
` A. I'm not.
` Q. What's a mycologist?
` A. Mycologist is the one who knows -- who
`has expertise in -- in mycology regarding the
`fungus.
` Q. What is mycology?
` MR. SEGREST: Objection. Foundation.
` A. Science of fungus.
`BY MR. MAURER:
` Q. Have you ever formulated any
`pharmaceutical compounds containing boron?
` A. We formulated quite a few products
`containing boron as a part of our lab exercise.
` Q. Which lab exercise was that?
` A. Well, in pharmaceutics we have the
`laboratory experiments to formulate suppositories
`and certain other dosage forms, the semisolids and
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 22
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 23
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`such things. So there we have developed the
`boron-containing topical products.
` Q. Have you ever formulated any
`pharmaceutical compound containing boron for
`topical treatment of nail disease?
` A. No.
` Q. What was the compound that you used in
`your lab experiments?
` A. We used sodium borate, borax, boric
`acid.
` Q. Can you describe the structure of the
`nail as it relates to the topical treatment of
`onychomycosis?
` A. Could you repeat the question, please?
` Q. Sure.
` Can you describe the structure of
`the nail as it relates to the topical treatment of
`onychomycosis?
` MR. SEGREST: Objection. Scope and
` foundation.
` A. Question is vague. I want specific
`questions. Can you break it down to simpler,
`please? You know, structure of nail, I don't know
`whether you're asking about the nail plate or
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 23
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 24
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`exactly...
`BY MR. MAURER:
` Q. Why don't we start there.
` What is the nail plate?
` A. The nail plate has three layers: The
`dorsal, middle, and the ventral layer.
` Q. Okay. What is the nail plate?
` A. The nail plate is just a matrix of
`keratin. It's made up of keratinocytes.
` Q. So the nail plate is the -- what we
`would call -- nonscientists would call the nail
`itself?
` A. Nail. That's right.
` Q. Are you familiar with the term "nail
`bed"?
` A. Yes.
` Q. What is the nail bed?
` A. The nail bed is the soft tissue
`underneath the nail plate.
` Q. And in onychomycosis, where is the
`infection located?
` A. Infection is located on the nail plate,
`in the nail bed, and in the nail matrix.
` Q. And when you say nail matrix, what is
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 24
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 25
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`that?
` A. Nail matrix is more to the proximal side
`of the nail bed.
` Q. And when you say "proximal side of the
`nail bed," you're talking about the underneath of
`the nail?
` A. Underneath of the nail.
` Q. So the side that is closest to -- the
`side between the nail plate and the nail bed?
` MR. SEGREST: Object to form.
` A. No.
`BY MR. MAURER:
` Q. Okay.
` A. Nail matrix is a continuation of the
`nail bed.
` Q. Is it underneath the nail bed, or is it
`on top of the nail bed?
` MR. SEGREST: Objection. Form.
` A. It's actually -- see, the nail grows
`from the nail matrix. It's underneath the nail
`fold, rather.
`BY MR. MAURER:
` Q. And where is the nail fold?
` A. There are lateral nail folds and the
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 25
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 26
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`proximal nail fold.
` Q. Is the nail fold the portion of the --
`at the base of the nail?
` A. There are lateral nail folds and the
`proximal nail fold.
` Q. So there's a proximal nail fold, which
`is at the bottom, and lateral folds at the sides,
`correct?
` A. Correct. That's right.
` Q. Are you familiar with how onychomycosis
`is diagnosed?
` A. Yes.
` Q. And how is it diagnosed?
` A. Basically, by the appearance of the
`nail, and then also do some culture tests to
`identify the fungus.
` Q. In the case of -- in diagnosis of
`onychomycosis by visual inspection, is the
`clinician able to determine the causative
`pathogen?
` MR. SEGREST: Object to the form and the
` scope.
` A. Not really.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 26
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 27
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`BY MR. MAURER:
` Q. Could a clinician -- strike that.
` Are there different types of
`onychomycosis?
` A. There are different ways of classifying
`it. So there's dorsal ungual and lateral ungual,
`and then there is onychomycosis that affects the
`nail bed. So there are different ways of
`classifying. Clinical classifications are
`different.
` Q. Are you familiar with distal and lateral
`subungual --
` A. Right. Yeah.
` Q. -- onychomycosis?
` A. Right. Yeah.
` Q. What is that?
` A. Distal and subungual is more towards the
`front side of the nail plate, and subungual would
`be underneath the nail plate.
` Q. Is there any particular pathogen that's
`associated with this distal and lateral subungual
`onychomycosis?
` MR. SEGREST: Objection to form.
` A. So, generally, onychomycosis is caused
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 27
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 28
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`by dermatophytes.
`BY MR. MAURER:
` Q. Are there any particular dermatophytes
`that are associated with distal and lateral
`subungual onychomycosis?
` A. T. rubrum is the one, and then
`T. mentagophyte is the other one. There is
`sometimes coexistence of Candida albicans with
`that.
` Q. Are you familiar with superficial white
`onychomycosis?
` MR. SEGREST: Objection to form.
` A. Yeah. You know, there are different
`ways of classifying it, depending on the
`clinical -- depending on the official diagnosis.
`So superficial white onychomycosis is -- it's the
`nail plate, but here with -- it's parts of fungal
`infection.
`BY MR. MAURER:
` Q. Any other types that you're aware of?
` A. No, I'm not.
` Q. Have you heard of proximal subungual
`onychomycosis?
` A. Yeah. Something similar to the distal
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 28
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 29
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
`subungual. A proximal subungual would be more
`localized towards the nail fold.
` Q. What about total dystrophic mycosis?
` A. That's like the whole nail apparatus
`being affected.
` Q. What about minor subungual
`onychomycosis?
` A. Just depending on the severity, they
`call it minor.
` Q. If it's not severe, it's called minor?
` A. It is -- if it's not severe, yes.
` Q. And when you -- what's the difference
`between severe and not severe?
` A. That's a clinical term, you know.
` Q. Based on the depth of the infection in
`the nail plate?
` MR. SEGREST: Objection to scope.
` A. Not clear.
`BY MR. MAURER:
` Q. Do you know?
` A. No, not clear. I'm not clear about
`that.
` Q. Have you formulated a compound for
`topical treatment of onychomycosis?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 29
`
`Anacor Exhibit 2018
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Page 30
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` S. Narasimha Murthy, Ph.D.
` A. Yes, I did.
` Q. And what have you formulated?
` A. Well, we formulated -- "we," I mean my
`group, do a lot of research on transungual
`delivery and development of formulations. So we
`worked on a formulation for the delivery of
`terbinafine. We also worked on the delivery of
`trans -- terconazole by a technical assigned
`process. I worked on a drug called ciclopirox.
`And also we developed some -- we screened
`enhancers for a compound called ER12, the project.
`Project was sponsored by Arnold Therapeutics.
` Q. That was a development candidate for
`clinical compound?
` A. I have no clue. They just asked me to
`screen the enhancers.
` Q. Okay. Are you familiar with the use of
`petroleum jelly in the formulation of topical
`treatments for

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket